Daiichi Sankyo plans first Japan filings for prasugrel after new Phase III data
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo's oral antiplatelet agent prasugrel has met the primary endpoint in a second Japanese Phase III study, clearing the way for its first approval filings in the country that are now expected sometime in the first half of the fiscal year beginning 1 April.